The Role Of Minimally Invasive Surgeries In The Hyperparathyroidism Treatment Market

By Author: Money Singh
Total Articles: 28
Comment this article

Hyperparathyroidism is a condition characterized by the overproduction of parathyroid hormone by one or more of the parathyroid glands, usually located in the neck region. Parathyroid hormone plays a crucial role in calcium homeostasis and regulating its levels in the blood. High levels of parathyroid hormone lead to increased calcium levels in the blood. Common symptoms of hyperparathyroidism include fatigue, bone and joint pain, kidney stones, and mental clouding. Conventionally, surgical removal of the affected parathyroid gland(s), known as parathyroidectomy, has been the primary treatment option. However, advances in therapeutic options have provided safer alternatives to conventional surgeries.

The Global Hyperparathyroidism Treatment Market is estimated to be valued at USD 780.1 Mn in 2024 and is expected to reach USD 991.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031

Key Takeaways

Key players operating in the hyperparathyroidism treatment market are AbbVie, Amgen, Dexcel Pharma, Eisai Inc., Teva Pharmaceutical Industries Ltd.

Rising prevalence of ...
... hyperparathyroidism and growing awareness regarding its treatment options are expected to drive the market during the forecast period. According to research, an estimated 1-3 individuals per 1,000 have hyperparathyroidism.

Advances in minimally-invasive treatments such as focused ultrasound therapy are gaining popularity due to benefits like targeted treatment, reduced surgery time, shorter hospital stay, and quicker recovery time compared to conventional parathyroidectomy.

Market Trends

Growing preference for minimally-invasive therapies: Minimally-invasive treatments like focused ultrasound therapy and endoscopic parathyroidectomy are emerging as preferred alternatives to conventional surgeries due to benefits like smaller incisions, reduced pain and scarring.
Increasing research on pharmacological therapies: New drug candidates targeting parathyroid hormone production and signaling pathways are being evaluated which can potentially offer non-surgical options for Hyperparathyroidism Treatment.

Market Opportunities

Untapped emerging markets: Emerging countries in Asia Pacific and Latin America offer significant growth opportunities due to increasing healthcare expenditure, rising awareness, and growing patient populations.

Focus on combining pharmacological and minimally-invasive therapies: Integrating drug therapies with focused ultrasound or gamma surgery can help achieve effectiveness of surgery with the convenience of oral medications for better management of hyperparathyroidism.

Impact of COVID-19 on Hyperparathyroidism Treatment Market Growth

The COVID-19 pandemic has negatively impacted the global hyperparathyroidism treatment market growth. During the initial outbreak phase, fewer patients visited hospitals and clinics for diagnosis and treatment of hyperparathyroidism. This led to a decline in the demand for drugs and surgery therapies. However, the market is expected to recover post-pandemic as diagnosis and treatment resume at full pace. Telemedicine adoption increased considerably during this period to provide continuity of care.

Pharmaceutical companies faced disruptions in manufacturing and supply chains globally due to lockdowns and social distancing measures. This created short-term shortages of certain hyperparathyroidism drugs. Their prices also increased temporarily. With resumption of operations, constant supply is being ensured while improving staff safety. The pandemic emphasized the need for decentralization of production facilities.

It also accelerated digital transformation in healthcare. Online consultations, remote patient monitoring, and automated refill systems are being leveraged more extensively for efficient long-term management of the condition. This shift towards telehealth and home healthcare will aid market growth even in the post-COVID era. Vaccination drives are underway to curb infections and enable unhindered access to pathology labs and surgical facilities.

North America dominates the hyperparathyroidism treatment market in terms of value. This is majorly attributed to the high and growing prevalence of hyperparathyroidism in the US. Favorable reimbursement policies and advancement of diagnostic procedures and therapies also contribute significantly. Awareness levels regarding the condition are high among patients and physicians. Commercial availability of innovative drugs has further boosted adoption.

Asia Pacific is poised to be the fastest growing region for the hyperparathyroidism treatment market. Increasing healthcare expenditure, urbanization, rising obesity, advancement of pathology infrastructure and elevating standards of living are some key factors driving market growth. Government initiatives to strengthen public health programs also promote demand for diagnosis and management of related endocrine disorders like hyperparathyroidism.

Get More Insights On- Hyperparathyroidism Treatment Market

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)